Robert Seth Shapiro, MD | |
346 Waianuenue Ave, Hilo, HI 96720 | |
(808) 961-9040 | |
Not Available |
Full Name | Robert Seth Shapiro |
---|---|
Gender | Male |
Speciality | Dermatology |
Experience | 42 Years |
Location | 346 Waianuenue Ave, Hilo, Hawaii |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104999770 | NPI | - | NPPES |
C02376 | Other | HI | HMSA LOCAL BLUE CROSS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 5573 (Hawaii) | Primary |
Mailing Address | Practice Location Address |
---|---|
Robert Seth Shapiro, MD 346 Waianuenue Ave, Hilo, HI 96720 Ph: (808) 961-9040 | Robert Seth Shapiro, MD 346 Waianuenue Ave, Hilo, HI 96720 Ph: (808) 961-9040 |
News Archive
In the third Series paper, Means restriction for suicide prevention, Professor Paul Yip of the Centre for Suicide Research and Prevention, University of Hong Kong, China, and colleagues review the evidence for means restriction in preventing suicides. Despite the fact that some suicide methods are difficult to restrict, the researchers highlight the fact that means restriction remains one of the most effective ways to reduce suicide rates.
Preliminary research suggests that testosterone replacement therapy for men with low testosterone levels appears to have little effect on the prostate gland, contrary to some reports that this therapy may be harmful, according to a study in the November 15 issue of JAMA: The Journal of the American Medical Association.
Abbott announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market.
The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.
› Verified 2 days ago
Charles Thomas Mauro Iv, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 868 Ululani St, Suite 103, Hilo, HI 96720 Phone: 808-961-3427 |